investor consid report singl factor make invest decis
total revenu million
nephro inc headquart south orang new jersey water purif compani develop sell high perform filter ultrafilt filter
pore size micron primarili hospit prevent infect waterborn pathogen dialysi center remov biolog
contamin water bicarbon concentr acquisit decemb expand neph commerci market footprint includ food servic
hospit industri compani own subsidiari specialti renal product develop stage compani focus improv therapi
patient renal diseas
initi nephro inc specul buy rate price target per share
nephro substanti growth potenti within water purif market portfolio filter
ultrafilt product primari growth opportun increas custom penetr
us hospit dialysi center well increas usag exist custom estim neph
custom consist approxim us hospital/dialysi center estim
believ neph specialti renal product subsidiari gener hemodiafiltr form renal
replac therapi system fda clearanc receiv provid signific increas
oper result manag estim specialti renal product subsidiari could gener annual
revenu approxim million gener product achiev market penetr
april neph announc preliminari revenu increas approxim million
driven increas custom base
project net loss million per share revenu growth million
revenu forecast line compani guidanc
project net loss break-even per share revenu growth
million reflect full year contribut launch waterborn pathogen diagnost test
devic increas recur revenu neph expand hospit dialysi hospitality/foodservic
custom base narrow net loss forecast reflect gross margin expand
estim oper expens margin improv estim
pleas view disclosur page
initi coverag nephro inc specul buy rate price target
per share base revenu forecast forecast reflect growth compani custom base
primarili hospit dialysi center drive recur revenu water filtrat filter replac cycl
well launch new waterborn pathogen diagnost test devic requir replac
collect filter biochem dna/rna test kit time test perform
rate reflect anticip growth nephro commerci water purif product portfolio includ
high perform filter ultrafilt filter pore size micron well decemb
acquisit biocon aether brand water filter expand market includ compani
hospitality/foodservic industri rate reinforc specialti renal product subsidiari
receiv fda clearanc gener hemodiafiltr form renal replac therapi remov
middle-molecular-weight solut system anticip clearanc could occur end
price target per share impli share could doubl next twelv month
accord thomson reuter averag trail twelve-month price-to-sal multipl compani
healthcar equip suppli sector respect estim sale growth
neph trail twelve-month price-to-sal multipl respect
estim sale growth appli current trail sale multipl ep
forecast discount execut risk obtain year ahead price target approxim per share
higher valuat nephro like support rapid quarterli sale growth narrow oper
loss receiv fda clearanc gener hemodiafiltr system forecast
neph oper loss narrow break-even loss million compani gener
cash earn cash burn million investor note exclud
compani specialti renal product subsidiari chang cash neglig
believ nephro inc suitabl high-risk toler investor seek exposur micro cap
nephro inc headquart south orang new jersey commercial-stag water purif compani
develop sell high perform filter ultrafilt filter pore size micron
compani oper own subsidiari call specialti renal product srp develop stage
medic devic compani focus improv therapi patient renal diseas srp primari goal
complet develop second-gener hemodiafiltr dialysi hdf first-gener
product us food drug administr clear medic devic enabl nephrologist
kidney doctor provid hdf treatment patient end stage renal diseas hdf form renal
replac therapi compar standard hemodialysi remov middle-molecular-weight
compani medic devic product mostli classifi ultrafilt primarili use hospit
prevent infect water-born pathogen legionella pseudomona other dialysi center
remov biolog contamin water bicarbon concentr sinc compani ultrafilt
captur contamin small micron size minim exposur wide varieti bacteria virus
fungi parasit endotoxin
neph expand commerci segement nanoguard product line decemb acquisit
biocon manufactur market aether brand water filter compani expand product line
aether brand includ addit water filtrat purif technolog primarili focus
improv odor tast reduc scale heavi metal filter water aether-brand water
filter sold primarili custom food servic conveni store hospit industri compani
like cross-sel aether water filter exist hospit custom
nephro ultrafilt pore size smaller convent filter
healthcar profession affili columbia univers medic center/new york-presbyterian
hospit found nephro inc nephro develop commerci hemodiafiltr altern method
standard hemodialysi recent year compani expand oper includ commercial-stag liquid
purif high perform filter ultrafilt
product portfolio applic
compani develop sell water filtrat product use medic commerci applic
compani ultrafilt competitv
microfilt base pore size see pictur
right
compani product portfolio broken
target market target market
includ hospit healthcar
dialysi center commerci facil
locat within hospitality/foodservic
hospit healthcar facil
primari purpos neph product hospit healthcar facil filtrat water
wash drink order enhanc infect control compani filter produc water suitabl
wound cleans clean equip use medic procedur wash surgeon hand etc neph
ultrafilt pictur right
compani product portfolio
hospit
hydraguard hydraguard
obtain fda clearanc
market either dual-stag singl
stage product and/or in-lin protect
water born pathogen note
chart right competit advantag
nephro filter product life cycl typic longer convent filter thu reduc
annual cost ownership reduc cost ownership includ reduct replac frequenc also
lower labor cost allow fewer physic trip high-risk area hospit intens care unit
neonat intens care unit burn transplant unit
compani product offer market use filter potabl safe drink water feed ice machin
sink shower sourc clean medic equip endoscop washer surgic room
critic control point hospit water manag plan ice machin constantli use
patient hospit staff compani dsu-h
dual-stag design provid redund self-
work standard cartridg hous
protect compani forward-flush
design pictur right
sink shower hospit set one primari sourc patient exposur given transfer
bacteria atom separ someth
fine particl process break bulk liquid
droplet compani hand held microfilt
shower pictur right provid point-of-us
protect filter/ultrafilt use shower
sink within hospit pictur right
compani anticip addit legionella
pathogen group gram-neg bacteria risk
center medicar
medicaid servic site inspect hospit
long term care facil increas focu infect control personnel facil engin across
hospit industri focu provid opportun compani market expand custom
base within us hospit dialysi center
nephro dialysi ultrafilt fda clear design use filter water bi-carbon
use provid hemodialysi dialysi machin special filter call artifici kidney dialyz use
clean patient blood qualiti water bicarbon concentr devic complet water treatment
system serv remov biolog contamin must use conjunct water treatment
dialysi clinic dedic water purif system produc water bicarbon concentr two
essenti ingredi make liquid need remov wast materi blood
compani fda clearanc
follow portfolio medic devic product use
dialysi set product pictur right
dsu-d ssu-d ssumini in-lin
micron ultrafilt provid protect bacteria
virus endotoxin product use filter
water follow treatment revers osmosi process solvent pass porou membran
opposit direct system filter bicarbon concentr ultrafilt sold use water line
bicarbon concentr line lead dialysi machin filter portabl revers osmosi
machin product last dsu-d offer design two-stag filter enabl
extra filter stage occur need ssu-d offer singl stage design see pictur
ssumini compani newest offer use filter bicarbon concentr water dialysi
compact design econom solut low flow rate
march compani receiv fda clearanc market endopur cartridg
ultrafilt product offer single-stag protect bacteria virus endotoxin last
primarili use filter water follow treatment revers osmosi ro system typic
larg ro system provid ultrapur water entir dialysi clinic endopur offer avail
three configur cartridge-bas plug play product requir plumb instal
compani market portfolio proprietari product nanoguard aether brand use
commerci industri food servic set
commerci nanoguard product line intern cross-sect pictur next page provid ultrafiltr
technolog filter bacteria virus water decemb compani acquir
biocon whose product market aether brand acquisit expand compani product
line water filtrat purif technolog includ improv odor tast reduc scale heavi
metal filter water aether filtrat system primari sold hotel conveni store quick
servic restaur new vertic compani offer also cross-sel
opportun within exist base hospit custom order improv odor tast patient
nanoguard-d in-lin ultrafilt provid dual-stag single-stag
retent organ inorgan particl larger dalton dalton unifi atom mass unit
dalton classifi middl size molecular weight
compani three addit nanoguard product label
design singl stage ultrafilt cartridg
retain organ inorgan particl larger dalton
nanoguard plug everpur filter produc competitor
manifold product label design fit
cartridg hous design flushabl cartridg
avail size
compani aether brand repres canist filter pictur
right portfolio four filter primarili sold directli
hotel conveni store quick servic restaur primari
competit aether product cuno brand
four aather brand filter sediment retain dirt rust particl solid potabl water
carbon block carbon-bas filter improv tast odor reduc level chlorin heavi
miner scale filter use proprietari technolog reduc develop lime scale build-up
downstream equip surfac carbon scale filter combin carbon-bas filter scale
technolog singl filter
nephro found base gener hemodiafiltr hdf devic compani gener
devic develop altern dialysi modal combin benefit standard hemodialysi hf
singl therapi clear toxin use diffus convect compani realiz hdf
wide use us wide use europ
compani form new subsidiari specialti renal product inc own neph
order drive develop second-gener hemodiafiltr hdf system gener hdf
system construct fund fund directli rais
subsidiari includ million seri prefer stock financ septemb
fda clearanc receiv market new hdf system
commenc us
nephro develop design patent olpur hemodiafiltr
modul modul pictur right part gener hdf
devic devic design util standard hd machin perform in-lin
hemodiafiltr hdf therapi hd machin control monitor basic
treatment function would normal modul free stand
movabl devic place next either side standard hd machin
order provid hdf therapi modul connect clinic water suppli
drain electr goal gener hdf system reduc setup
changeov time space requir least system cost
new system also elimin nightli mainten easier oper order make
gener hdf effici market dialysi healthcar facil design attach
exist hemodialysi hd machin gener devic need dispos filter tube set order
olpr pictur right two-stag hdf filter stage one
incom blood flow portion hollow fiber make annular area
outsid fiber bundl discharg substitut header region
end substitut fluid infus substitut header mix blood
exit first stage stage two mixtur flow remain
portion hollow fiber core area fiber bundl pass
hollow fiber second stage blood enter center header region two-port
cap exit blood outlet port devic
sinc compani shift sale model emphas build network value-ad resel
target market hospit dialysi center commerci establish sale commerci establish
supplement direct sale effort stem sale team compani decemb acquisit
biocon aether brand water filter
compani establish oper medic market experienc excess annual total
revenu growth sinc implement resel sale model resel relationship began
small mom pop compani servic water mainten need medic facil
hospit satellit facil dialysi center servic compani sell nephro filter
facil instal servic replac requir rapid sale growth due
compani expand region servic provid medic facil growth continu relationship
forg nation servic provid compani anticip also grow outsid medic facil
market exist group resel relationship
compani product develop strategi launch product next coupl year drive
revenu growth end neph plan launch waterborn pathogen diagnost product
potenti serv exist new custom hospit medic facil market new product
offer serv drive revenu two way one-tim purchas devic recur
purchas nephro collect filter dna/rna test kit use time test perform
devic process provid result singl liter water sampl approxim one hour compar
current process identifi water born pathogen sampl must sent lab take
day receiv result
neph gener hemodiafiltr hdf system pictur bottom prior page avail
receiv clearanc fda compani anticip fda clearanc launch follow
immedi launch manag anticip compani hdf system potenti use
approxim site exist relationship without signific invest sale market
compani believ market penetr could provid approxim million annual dispos revenu
sinc compani built portfolio product serv need custom set period time
replac replac cycl strategi develop manag recur revenu
stream estim compani product use approxim medic facil
translat annual recur revenu growth custom base expand
statist report publish american hospit associ estim hospit
approxim bed staf ibisworld estim number us hospit could reach
nearli growth like attribut age us popul
demand hospit servic increas
accord us offic diseas prevent health promot healthcar associ infect hai
given time affect approxim everi patient infect lead loss life
estim cost us health care system billion dollar year one caus hai
waterborn bacteria virus bacteria virus present age infrastructur healthcar
facil plumb system one strateg benefit potenti benefit nephro effort sell product
us hospit current estim compani hospit custom issuanc
center clinic standard qualiti center medicar medicaid servic
surveyor review polici procedur report document water manag implement result
verifi facil compliant exist requir
us offic diseas prevent health promot healthi peopl initi drive addit
awar regard hai hai occur type care set includ acut care hospit ambulatori
surgic center dialysi facil outpati care long-term care facil nurs home
rehabilit facil peopl initi reflect commit us depart
human servic hh prevent hai
dialysi clinic need dedic water purif system produc water bicarbon concentr two
essenti ingredi make dialys liquid remov wast materi blood accord
american journal kidney diseas approxim dialysi clinic unit state accord
statist nation institut diabet digest kidney diseas
american afflict kidney failur individu dialysi roughli
live function kidney transplant nephro estim hemodialysi machin
oper us compani gener hdf offer like market upgrad exist
hemodialyi machin thu avoid larg capit invest whole new hdf machin larger
ibisworld estim dialysi equip manufactur industri grow annual reach billion
growth sustain age us popul ibisworld predict intern trade
like grow due strengthen global demand dialysi treatment latter could benefici nephro
gener hdf product wide use outsid us
ibisworld all-encompass report call us accommod food servic industri
primarili compris compani hospit hotel casino etc food servic restaur
conveni store etc ibisworld anticip number establish industri
million million growth good overal number establish key
nephro growth littl penetr market small increas hospitality/food servic
custom make signific impact top line result
basi forecast
primari growth driver expand compani resel network turn increas compani
custom portfolio water filtrat filter leverag compani experi
grow number custom use filter defin replac cycl exist depend type
filter purchas recur revenu stream sustain forecast period
anticip compani core oper like least break-even cash basi invest
made specialti renal product subsidiari result oper loss million cash burn
million forecast break-even oper basi cash earn
anticip gross margin expans estim gross margin
improv due primarili increas recur revenu replac life-cycle
project oper expens million estim million level
expens includ cost develop market new exit product well expans compani
project revenu growth million due increas instal base product stem
new custom expans exist custom gross profit increas million due
primarili sale growth gross margin compar
project oper loss narrow million compar loss million oper expens
increas million anticip sg expens increas million support sale
growth compani exist new aether brand filter anticip expens increas
million compani continu develop new product expect launch
next two year
non-oper expens consist interest expens compani interest expens
expens loss extinguish debt
project net loss million per share compar loss million per share
decemb compani feder state foreign net oper loss carryforward
project cash burn million increas work capit increas work capit
due primarili increas inventori use oper million capit expenditur
repay debt decreas cash million million decemb
project revenu increas million due primarili compani custom base expand
includ compani within food servic conveni store hospit industri well launch
waterborn pathogen diagnost product exist hospit custom gross profit increas
nearli million increas gross profit reflect revenu growth gross margin expand
compar estim improv gross margin reflect increas
number replac filter instal sale filter assay waterborn pathogen diagnost
project oper loss narrow break-even compar estim loss million
oper expens margin improv estim anticip oper expens
increas million project increas sg expens million due primarili
higher compens cost implement market initi support growth newli launch
product anticip expens million estim million compani
continu enhanc water filtrat product portfolio
project non-oper interest expens compar due lower debt balanc
project net loss break-even per share compar net loss million per share
project cash earn increas work capit increas work
capit due primarili increas inventori receiv oper cover
capit expens repay debt increas cash million decemb
result
total revenu increas approxim million compar million year-ago period
revenu growth due primarili sale new custom expans within exist custom account
gross profit increas million compar million reflect higher sale off-set part gross
margin contract year-ago period decreas gross margin reflect certain
ineffici manufactur distribut process
oper expens increas million million expens water
filtrat renal product segment increas million combin increas total
expens due increas spend develop compani second-gener hdf product
renal product segment increas off-set part reduc spend new filter
develop water filtrat segment sg expens increas
million million increas sg due primarili increas headcount stock-bas
compens expens market cost rent wareh ship well increas bad debt expens
profession fee increas oper expens partli off-set decreas expens
reflect lower amort expens stem amend licens suppli agreement
medica septemb extend term decemb decemb
non-oper expens compar interest expens decreas
due primarili lower averag debt balanc reflect payoff unsecur debt compani
record loss extinguish debt reflect remain debt discount debt repaid
expens decreas due primarili improv foreign
compani record incom tax benefit compar million incom tax benefit
reflect sale net oper loss research develop credit carryforward new jersey
econom develop author technolog busi tax certif transfer program net loss
million non-control interest loss compar compar loss
per share non-control interest gain loss
total revenu increas approxim million compar million year-ago period
revenu growth due primarili sale new custom expans within exist custom account
gross profit increas reflect higher sale off-set part gross margin contract
year-ago period oper expens increas million increas
oper expens driven cost doubl sg expens increas
million
non-oper expens compar year-ago period interest expens decreas
due primarili lower averag debt balanc
compani record incom tax benefit compar million incom tax benefit
reflect sale net oper loss research develop credit carryforward new jersey
econom develop author technolog busi tax certif transfer program net loss attribut
compani non-control interest loss compar incom
million per share non-control interest gain loss incom due
tax benefit
cash burn million million increas work capit result cash use oper
million increas work capit due primarili increas inventori proce sale
common stock approxim million proce sale subsidiari prefer share million
cover cash use oper capit expenditur repay debt increas million
million decemb
august compani enter loan agreement capit provid secur asset-
base revolv credit facil million payabl monthli base averag daili outstand
balanc rate equal plu prime rate per annum prime rate less decemb
current interest rate outstand balanc compani use revolv
facil work capit gener corpor purpos loan agreement term
automat renew august automat renew success period unless
cancel neph grant capit first prioriti secur interest asset includ account
receiv inventori secur oblig
march neph enter secur promissori note capit llc princip amount
approxim million decemb princip balanc excess million note
matur april unpaid princip accru annual interest
water filtrat market well establish compani manufactur point-of-us microfiltr product
pall corpor subsidiari danah corpor manufactur cuno everpur
brand water filtrat purif product respect nephro much smaller
less financi resourc larg compani domin water filtrat market howev
compani believ compet within water filtrat market develop market product
design meet critic specif custom need effect devic market offer filter
ultrafilt uniqu attribut product reliabl user-friendli easi instal perform
capabl extend life chang filter twice year compar competitor offer need
chang often pursu allianc and/or acquisit opportun joint product develop
market compani sell commerci dialysi center product highli competit
competit includ larg compani publicli trade us baxter intern inc freseniu
medic ag asahi kasei medic co ltd terumo medic corpor toray medic co ltd
intern compani publicli trade us braun melsungen ag nipro medic corpor
ltd nikkiso co ltd
compani own subsidiari specialti renal product develop stage compani focus
improv therapi patient renal diseas face intens competit within dialyz renal
replac therapi market compani success market depend abil meet
clinic goal nephrologist improv patient outcom remain cost-effect payer compani
compet supplier end-stag renal diseas esrd therapi suppli servic supplier
includ publicli trade compani freseniu medic ag inc two
primari machin manufactur hemodialysi
daron evan presid ceo sinc april serv compani board sinc novemb
chairman januari april mr evan life scienc execut
year financi leadership oper experi previous serv cfo inc
held variou posit scio inc vistakon inc divis johnson johnson mr evan
co-found appli neuron network dynam inc serv presid career began serv
variou role consult firm arthur littl booz allen hamilton mr evan manag director
poc capit llc director zumbro discoveri earli stage compani develop therapi resist
hypertens earn bs chemic engin rice univers master scienc biomed
engin joint program univers texa arlington southwestern medic school
mba fuqua school busi duke univers
andi astor cfo sinc februari sinc januari recent serv presid cfo
open sourc consult group previous serv vice presid asurion privately-own insur
compani co-found ceo softwar compani enterprisedb well vice presid webmethod
dun bradstreet prior experi includ hold variou role american manag system
shl/mci systemhous ernst young earn ba mathemat clark univers
wharton school univers pennsylvania
view princip risk underli stock
nephro inc yet turn profit decemb compani accumul deficit
million nearli million loss like continu diminish forecast period
lack profit could result compani inabl execut growth strategi diminish
compani oper signific complianc burden fdc act set law give author
drug administr fda overse safeti food drug medic devic cosmet
applic statut regul govern test label storag record keep distribut
sale market advertis promot nephro medic approv product violat fdc act
regulatori requir either respect compani ultrafilt time
product develop and/or approv process could subject neph enforc action fda
agenc would like advers effect busi financi condit result oper
product market sale kidney dialysi water-filtr product liabil risk event
product failur claim harm caus product oper voluntari recal could subject compani
claim proceed consum fda regulatori author would advers impact futur
sale revenu also meritless claim product liabil may costli defend compani
product liabil insur may abl maintain insur accept term
compani ensur exist product yet approv new product
develop futur approv market clearanc and/or approv process lengthi
uncertain requir substanti financi resourc well manag time effort like
costli difficult meet regulatori requir sale compani product mani countri
result compani global sale effort may slow materi could drain financi resourc continu
develop new product sale us
compani success depend part abil protect intellectu properti technolog
patent neph abl protect product method unauthor use third parti
extent product method develop cover valid enforc patent effect
maintain trade secret compani grant us patent expir variou time
assum properli maintain
protect provid compani patent patent applic issu may broad enough
prevent competitor introduc similar product market litig proceed relat
patent matter whether initi neph third parti expens time-consum regardless
whether outcom favor compani may requir divers substanti financi manageri
resourc
nephro enter licens suppli agreement medica italy-bas medic product
manufactur compani market sale certain filtrat product base upon proprietari
medisulfon ultrafiltr technolog licens suppli agreement medica expir decemb
period april decemb compani pay medica royalti rate
net sale filtrat product sold subject reduct result suppli interrupt pursuant
term agreement
new medic devic introduc market fda clearanc pre-market notif
section fdc act fda clearanc pre-market approv applic section fdc
act must obtain clearanc grant submit inform establish propos
devic substanti equival legal market medic devic medic devic fda
call pre-market approv section section pre-market clearanc process gener
faster simpler section pre-market approv process compani filter ultrafilt
medic devic gone approv process
devic clear process modif enhanc could significantli affect
safeti effect devic constitut major chang intend use devic requir
new pre-market notif submiss compani seek obtain section pre-market clearanc
new modifi devic filtrat product would need submit anoth pre-market
notif could costli time consum may divert financi manag resourc
product alreadi approv gener revenu us
execut offic director group outstand vote stock august larg
investor compani outstand vote stock owner could greatli influenc outcom
matter requir stockhold approv decis may may best interest
compani financi result equiti valu subject risk uncertainti includ competit
oper financi market regulatori risk and/or event risk may caus actual result differ
base calcul averag daily-volum share three month april
volum decreas compani float million share share outstand
million march
thousand
compani report taglich brother estim
thousand
compani report taglich brother estim
thousand
compani report taglich brother estim
thousand
compani report taglich brother estim
invest bank servic compani cover past month
